NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors

NEXT STORY
Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
PREV STORY
The Worldwide Esoteric Testing Industry is Expected to Reach $36.3 Billion by 2026 at a CAGR of 11.6% from 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Pendulum Therapeutics Announces Formation of Scientific and Medical Advisory Boards

author_avatar
NASDAQ Market News

Peer Health Exchange rolls out first version of selfsea—an inclusive health app co-designed by young people to support their mental health

author_avatar
NASDAQ Market News

Global Mice Model Market Research Report 2020: Increasing Implications of Mouse Clinical Trials (MCTs) for More Predictive Outcomes and Ongoing Innovations

author_avatar
NASDAQ Market News